Reaction
Hydrothorax reporting signals
As of the last recalculation, Hydrothorax appears in 824 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is BOSUTINIB (PRR 37.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bosutinib | 13 | 37.1 | 37.2 |
| Crizotinib | 16 | 32.4 | 32.4 |
| Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 11 | 31.8 | 31.9 |
| Gefitinib | 11 | 31.2 | 31.2 |
| Everolimus Tablets | 19 | 29.3 | 29.3 |
| Ribociclib | 30 | 24.9 | 24.9 |
| Eplerenone | 12 | 24.0 | 24.0 |
| Ado-Trastuzumab Emtansine | 7 | 21.1 | 21.2 |
| Letrozole Tablets | 38 | 20.9 | 20.9 |
| Exemestane | 17 | 20.4 | 20.5 |
| Sunitinib Malate | 27 | 17.9 | 17.9 |
| Imatinib | 12 | 17.4 | 17.4 |
| Goserelin | 9 | 17.1 | 17.1 |
| Letrozole | 39 | 16.7 | 16.7 |
| Sorafenib | 13 | 16.0 | 16.1 |
| Erlotinib | 6 | 15.8 | 15.8 |
| Erlotinib Hydrochloride | 7 | 14.2 | 14.2 |
| Nilotinib | 16 | 14.0 | 14.0 |
| Pemetrexed | 11 | 13.1 | 13.1 |
| Docetaxel Anhydrous | 33 | 12.8 | 12.8 |
| Docetaxel | 33 | 12.8 | 12.8 |
| Osimertinib | 16 | 12.8 | 12.8 |
| Everolimus | 25 | 12.8 | 12.8 |
| Dasatinib | 18 | 12.5 | 12.5 |
| Trastuzumab | 30 | 11.4 | 11.4 |
| Nivolumab | 36 | 9.8 | 9.8 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 10 | 8.2 | 8.2 |
| Atezolizumab | 11 | 7.2 | 7.2 |